Natalizumab treatment reduces microglial activation in the white matter of the MS brain
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received December 19, 2018
- Accepted in final form April 2, 2019
- First Published June 7, 2019.
Author Disclosures
- Marcus Sucksdorff, MD,
- Jouni Tuisku, MSc,
- Markus Matilainen, PhD,
- Anna Vuorimaa, BM,
- Sarah Smith, BSc,
- Joonas Keitilä, BM,
- Johanna Rokka, MSc, PhD,
- Riitta Parkkola, MD, PhD,
- Marjo Nylund, MSc,
- Juha Rinne, MD, PhD,
- Eero Rissanen, MD, PhD and
- Laura Airas, MD, PhD
- Marcus Sucksdorff, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Received research support from (1)The Finnish Medical Foundation and from (2)The Finnish MS Foundation
NONE
NONE
NONE
NONE
NONE
NONE
- Jouni Tuisku, MSc,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Markus Matilainen, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Anna Vuorimaa, BM,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Received a personal research grant from the Finnish MS Foundation.
NONE
NONE
NONE
NONE
NONE
NONE
- Sarah Smith, BSc,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Joonas Keitilä, BM,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Johanna Rokka, MSc, PhD,
NONE
NONE
NONE
NONE
(1) HDAC6 INHIBITORS AND IMAGING AGENTS
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) Sigrid Jus?lius Foundation (2) Emil Aaltonen Foundation (3) Maud Kuistila Memorial Foundation (4) The Scandinavian Society of Clinical Physiology and Nuclear Medicine
NONE
NONE
NONE
NONE
NONE
NONE
- Riitta Parkkola, MD, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Marjo Nylund, MSc,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Juha Rinne, MD, PhD,
I serve as a consultant neurologist for Clinical Research Services Turku (CRST) Ltd.
NONE
NONE
I currently serve as an associate editor of Journal of Movement Disorders
NONE
NONE
NONE
NONE
NONE
My duties as a consultant for CRST involve participating in contract research with pharmaceutical companies.
NONE
NONE
(1) Academy of Finland, project #310962, Research grant, years 2017-2021
NONE
(1) Sigrid Juselius Foundation
NONE
NONE
NONE
NONE
NONE
NONE
- Eero Rissanen, MD, PhD and
(1) Biogen Idec, advisory board honoraria
NONE
(1) Teva Finland, speaker honoraria (2) Biogen Idec, speaker honoraria (3) Roche, speaker honoraria
NONE
NONE
NONE
NONE
(1) Merck, professional consultation fee
NONE
NONE
NONE
NONE
(1) State research funding, The expert responsibility area of the Turku University Hospital; personal study grant
NONE
(1) The Finnish Medical Foundation (2) The Finnish MS Foundation, personal study grant
NONE
NONE
NONE
NONE
NONE
NONE
- Laura Airas, MD, PhD
(1) Roche (2) Genzyme (3) Novartis (4) Merck
NONE
(1)Merck, Speaker honoraria, (2) Roche, Speaker honoraria
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) Biogen Idec (2) Genzyme
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- From the Turku PET Centre (M.S., J.T., M.M., A.V., S.S., J.K., J. Rokka, M.N., J. Rinne, E.R., L.A.), Turku University Hospital and University of Turku; Division of Clinical Neurosciences (M.S., M.N., J. Rinne, E.R., L.A.), Turku University Hospital and University of Turku; and Department of Radiology (R.P.), University Hospital and University of Turku, Finland.
- Correspondence
Dr. Sucksdorff marsuc{at}utu.fi
Article usage
Cited By...
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Cutaneous α-Synuclein Signatures in Patients With Multiple System Atrophy and Parkinson Disease
Dr. Rizwan S. Akhtar and Dr. Sarah Brooker
► Watch
Related Articles
- No related articles found.
Topics Discussed
Alert Me
Recommended articles
-
Article
Insights into disseminated MS brain pathology with multimodal diffusion tensor and PET imagingSvetlana Bezukladova, Jouni Tuisku, Markus Matilainen et al.Neurology: Neuroimmunology & Neuroinflammation, March 02, 2020 -
Article
Microglial activation, white matter tract damage, and disability in MSEero Rissanen, Jouni Tuisku, Tero Vahlberg et al.Neurology: Neuroimmunology & Neuroinflammation, March 06, 2018 -
Articles
Increased PK11195 PET binding in the cortex of patients with MS correlates with disabilityMarios Politis, Paolo Giannetti, Paul Su et al.Neurology, July 03, 2012 -
Article
Natalizumab in progressive MSResults of an open-label, phase 2A, proof-of-concept trialJeppe Romme Christensen, Rikke Ratzer, Lars Börnsen et al.Neurology, March 28, 2014